In addition, Spanoudakis et al found that higher levels of RANKL expressed by iNKT cells in peripheral blood and especially BM of MM patients as part of a myeloma‐specific dysfunctional iNKT cell phenotype that could contribute to osteoclast activation and bone destruction as well as tumour immune evasion.39 Owing to the experiment of Spanoudakis et al did not involve mechanism research and the lack of related researches about iNKT in myeloma bone disease, further experiments in vitro or vivo need to be performed. The gene discussed is TNFSF11; the disease is neoplasm.